• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氨基四氢萘对兔眼压及瞳孔功能的影响。

Effects of aminotetralins on intraocular pressure and pupillary function in rabbits.

作者信息

Burke J A, Chang F W, Potter D E

出版信息

J Auton Pharmacol. 1984 Sep;4(3):185-92. doi: 10.1111/j.1474-8673.1984.tb00095.x.

DOI:10.1111/j.1474-8673.1984.tb00095.x
PMID:6490680
Abstract

Aminotetralin compounds, A-6, 7-DTN and TL-99, produced bisphasic changes in intraocular pressure (IOP) and pupillary dilatation in rabbits. The rise in IOP appeared to result from an action on extraocular muscles because this effect was not produced by either compound in rabbits with transected extraocular muscles. The ocular hypotensive action of A-6, 7-DTN and TL-99 was markedly attenuated in sympathectomized rabbits indicating that this action resulted from suppression of sympathetic neuronal activity. Inhibition of ocular hypertension induced by waterloading by both compounds and suppression of the IOP recovery rate by A-6, 7-DTN suggested that the latter compound lowered IOP, in part, by inhibiting aqueous humor formation. The ocular hypotensive action of A-6, 7-DTN was antagonized by pretreatment with sulpiride, but not by yohimbine, indicating that dopamine receptors are involved in the response. These studies demonstrated that dopamine agonists can lower IOP and suggest that these types of drugs might prove useful in the therapy of open-angle glaucoma.

摘要

氨基四氢萘化合物A - 6、7 - DTN和TL - 99可使兔眼压(IOP)和瞳孔散大出现双相变化。眼压升高似乎是由于对眼外肌的作用所致,因为在眼外肌横断的兔中,这两种化合物均未产生此效应。在去交感神经的兔中,A - 6、7 - DTN和TL - 99的眼降压作用明显减弱,表明该作用是由交感神经神经元活动的抑制引起的。两种化合物均抑制水负荷诱导的高眼压,且A - 6、7 - DTN抑制眼压恢复速率,提示后一种化合物部分通过抑制房水生成来降低眼压。舒必利预处理可拮抗A - 6、7 - DTN的眼降压作用,而育亨宾则不能,表明多巴胺受体参与了该反应。这些研究表明多巴胺激动剂可降低眼压,并提示这类药物可能对开角型青光眼的治疗有用。

相似文献

1
Effects of aminotetralins on intraocular pressure and pupillary function in rabbits.氨基四氢萘对兔眼压及瞳孔功能的影响。
J Auton Pharmacol. 1984 Sep;4(3):185-92. doi: 10.1111/j.1474-8673.1984.tb00095.x.
2
Alteration in ocular function induced by phenylethylamine analogs of dopamine.多巴胺苯乙胺类似物引起的眼功能改变。
Curr Eye Res. 1984 Jun;3(6):851-9. doi: 10.3109/02713688409000798.
3
Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist.7-羟基-2-二丙基氨基四氢萘的眼部作用机制及作用部位:一种多巴胺(3)受体激动剂
J Pharmacol Exp Ther. 2000 Jun;293(3):710-6.
4
Ocular effects of a N,N-disubstituted 5-OH aminotetralin (N-0437): evidence for a dual mechanism of action.一种N,N-二取代的5-羟基氨基四氢化萘(N-0437)的眼部效应:双重作用机制的证据。
Curr Eye Res. 1987 Nov;6(11):1319-26. doi: 10.3109/02713688708997557.
5
LY141865: a relatively selective DA2 agonist with complex ocular activity.LY141865:一种具有复杂眼部活性的相对选择性多巴胺D2受体激动剂。
J Ocul Pharmacol. 1988 Spring;4(1):19-28. doi: 10.1089/jop.1988.4.19.
6
Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist.κ阿片受体激动剂布瑞马唑辛对眼内流体动力学和虹膜功能的调节作用
Exp Eye Res. 2000 May;70(5):675-82. doi: 10.1006/exer.2000.0832.
7
Contributions of adenosine receptor activation to the ocular actions of epinephrine.腺苷受体激活对肾上腺素眼部作用的贡献。
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2054-61.
8
Mechanism of the ocular hypotensive action of ketanserin.酮色林的眼内压降低作用机制。
J Ocul Pharmacol. 1985 Summer;1(2):137-47. doi: 10.1089/jop.1985.1.137.
9
A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits.一种新型D2-多巴胺能和α2-肾上腺素能受体激动剂可使正常血压兔子的眼压显著且持久降低。
J Pharm Pharmacol. 2003 Jun;55(6):789-94. doi: 10.1211/002235703765951393.
10
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent.可生物降解的磷酸钙纳米颗粒作为一种新型载体用于递送一种潜在的降眼压药物。
J Ocul Pharmacol Ther. 2002 Dec;18(6):507-14. doi: 10.1089/108076802321021054.